Birch pollen allergic patients undergoing allergen specific immunotherapy also respond to minor allergen Bet v 2

The article presents the results of the study on the effectiveness and safety of sublingual allergen-specific immunotherapy in children at the age from 4 to 17 years old with spring polinosis and birch-pollen allergy syndrome, which were assessed using visual analogue and combination scales, provocative tests and the results of component resolved diagnosis.

Download Full-text

Birch pollen allergen‐specific immunotherapy with glutaraldehyde‐modified allergoid induces IL ‐10 secretion and protective antibody responses

Allergy ◽

10.1111/all.13774 ◽

2019 ◽

Cited By ~ 3

Author(s):

Michèle Myriam Rauber ◽

Hoi Ka Wu ◽

Britta Adams ◽

Julia Pickert ◽

Barbara Bohle ◽

...

Keyword(s):

Specific Immunotherapy ◽

Birch Pollen ◽

Antibody Responses ◽

Pollen Allergen ◽

Allergen Specific Immunotherapy ◽

Protective Antibody ◽

Birch Pollen Allergen

Download Full-text

Clinical efficacy of subcutaneous and sublingual allergen-specific immunotherapy of allergic rhinitis and conjunctivitis

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/rja389 ◽

2016 ◽

Vol 13 (6) ◽

pp. 63-69

Author(s):

I E Kozulina ◽

K S Pavlova ◽

O M Kurbacheva

Keyword(s):

Allergic Rhinitis ◽

Pollen Season ◽

Specific Immunotherapy ◽

Pharmacoeconomic Analysis ◽

Birch Pollen ◽

Cost Utility ◽

Efficacy And Safety ◽

Allergen Specific Immunotherapy ◽

Cost Efficacy ◽

The Cost

Objective. To evaluate the efficacy and safety of subcutaneous and sublingual allergen-specific immunotherapy (AIT), a comparative pharmaco-economic analysis. Materials and methods. The study included 60 patients with allergic rhinitis and conjunctivitis with or without asthma induced by birch pollen. In the first group patients received subcutaneous AIT (SCIT) by «Phostal - allergen of trees pollen», in the second group - sublingual AIT (SLIT) by «Staloral - allergen of birch pollen». Results. All patients after the SCIT or SLIT in the first pollen season noted a decrease in the severity of nasal and conjunctival symptoms (SMD -1,93 [95% CI -2,39; -1,47] and -1,57 [95% CI -2,39; -0,75] for groups 1 and 2, respectively) and a decrease in the rescue medication requirement (SMD -1,98 [95% CI -2,57; -1,39] and -1,86 [95% CI -2,61; -1,11] for groups 1 and 2, respectively). There were no statistically significant differences between the SCIT and SLIT efficacy. After AIT in both groups there was a significant reduction in the cost of medication and medical services (on average 5 times). In a comparative pharmacoeconomic analysis «cost/efficacy» and «cost/utility» was showed comparable results of SCIT and SLIT.

Download Full-text

Patient management plan for sublingual allergen specific immunotherapy with birch pollen allergen and the maintenance of patient compliance

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/rja1403 ◽

2020 ◽

Vol 17 (3) ◽

pp. 64-73

Author(s):

Olga V. Trusova ◽

Andrey V. Kamaev ◽

Irina V. Makarova

Keyword(s):

Side Effects ◽

Patient Management ◽

Specific Immunotherapy ◽

Birch Pollen ◽

Management Plan ◽

Allergen Specific Immunotherapy ◽

Treatment Termination ◽

Birch Pollen Allergen ◽

Retention In Treatment ◽

Patient Retention

BACKGROUND:Sublingual allergen-specific immunotherapy (SLIT) inefficiencie is mainly caused by non-compliance with the treatment regimen and premature treatment termination. AIM:Frequency and causes of dropouts determination in children receiving SLIT with birch pollen according to the pre-coseasonal protocol, and approbation of the developed visit-to-visit patient management plan (Plan). MATERIALS AND METHODS:332 cases of treatment with birch pollen in children are analyzed. 290 patients (72.1% boys, aged 518 years (9.82 years [5.93; 14.67]), received SLIT with birch pollen in 20122019. 42 patients received SLIT according to the Plan (69% boys, 8.95 years old [5.38; 11.79]) in 20172019. RESULTS:A low dropout frequency was noted in the 1st and 2nd year of therapy (2 years after the start of treatment, 85% patients continue it). However, only 63.1% complete 3 years of therapy, and 11% 4 years of therapy. It has been shown that experienced allergists have more efficient patient retention. The implementation of the Plan increased patient retention in treatment at the 3rdyear of treatment up to 82.9% (p=0.02). CONCLUSION:The study confirmed the main reasons for the withdrawal of patients from SLIT: doubts about the effectiveness, cost and side effects. A low dropout frequency was shown according to the results of the 1stand 2ndyears of therapy, but only a small proportion of patients (11%) receive 4 or more courses of therapy. Visit-to-visit Plan optimizes the patients management, reduces patients withdrawal from treatment and can be recommended for practical healthcare.

Download Full-text

Pollen allergy and household budget

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/rja852 ◽

2011 ◽

Vol 8 (4) ◽

pp. 79-83

Author(s):

M A Mokronosova ◽

M A Mokronosova

Keyword(s):

Quality Of Life ◽

Allergic Rhinitis ◽

Specific Immunotherapy ◽

Birch Pollen ◽

Pollen Allergy ◽

Direct Costs ◽

Middle Part ◽

Allergen Specific Immunotherapy ◽

Severity Of The Disease

The prevalence of the allergy to birch pollen is high in the middle part of russian Federation. the symptoms of allergic intermittent rhinitis appears in the first decade and lasted during all life. the severity of the disease is aggravated annually. the economic burden of allergic rhinitis includes direct, indirect and hidden costs. the indirect cost (disability and loss of productivity, hypoallergenic life arrangements) exceeds direct costs many times. allergen specific immunotherapy by pollen allergovaccines is unique kind of pathogenic management. asIt demonstrates significant improvement of the symptoms of rhinitis and asthma, quality of life. one of the main problems is high costs of asIt. economical models used in investigations on asIt cost effectiveness demonstrated lucre in the following 10 years of life after 3 year's course of asIt. In order to achieve high clinical result it is necessary to follow european standard's guidance on specific immunotherapy strictly.

Download Full-text